May 26, 2023, 16:50
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
May 22, 2023, 08:30
News
IR
English
Regulatory
MAR
Corporate Action
Other
May 22, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
May 11, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
May 11, 2023, 08:30
News
IR
English
Corporate Action
Other
Apr 28, 2023, 09:51
News
IR
Swedish
Correction
Regulatory
MAR
Report
Interim
Q1
mfn-cus-disclaimer
Apr 28, 2023, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 28, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q1
mfn-cus-disclaimer
Apr 20, 2023, 10:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 14, 2023, 08:45
News
IR
English
Corporate Action
Other
Apr 14, 2023, 08:45
News
IR
Swedish
Corporate Action
Other
Apr 04, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Apr 04, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Mar 31, 2023, 10:01
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 16, 2023, 14:30
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Feb 10, 2023, 11:20
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 09, 2023, 15:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 08, 2023, 23:59
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se